Loading clinical trials...
Loading clinical trials...
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.
The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy. The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular response will be achieved in patients not previously obtained with imatinib monotherapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Servicio de Hematologia, Hospital Universitario "José E. Gonzalez"
Monterrey, Nuevo León, Mexico
Start Date
October 1, 2012
Primary Completion Date
July 1, 2013
Completion Date
August 1, 2013
Last Updated
January 7, 2014
10
ACTUAL participants
Imatinib and Nilotinib
DRUG
Lead Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions